PI's General Responsibility for Biosafety


NEW -  Important Information for Investigators with International Collaborations

General Responsibility, the PI shall:

  • Initiate or modify no recombinant or synthetic nucleic acid molecule research which requires Institutional Biosafety Committee approval or notification prior to initiation (see Sections III-A, III-B, III-C, III-D, and III-E, Experiments Covered by the NIH Guidelines) until that research or the proposed modification thereof has been approved by the Institutional Biosafety Committee and has met all other requirements of the NIH Guidelines;
  • Investigate and report within 30 days any significant problems pertaining to the operation and implementation of containment practices and procedures, violations of the NIH Guidelines, or any significant research-related accidents and illnesses to:
    • Dr. Nicholas Carpino, Chair, IBC,
    • Mr. Christopher Kuhlow (Biological Safety Officer, EH&S),
    • Ms. Erin Augello (on behalf of the Institutional Biosafety Committee),
    • NIH/OBA, Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, MD 20892-7985 (20817 for non-USPS mail), 301-496-9838, 301-496-9839 (fax);
    • And other appropriate authorities (if applicable, e.g., Dr. Thomas Zimmerman, DLAR Director, when the work involves animal subjects),
    • Be adequately trained in good microbiological techniques;
    • Adhere to Institutional approved emergency plans for handling accidental spills and personnel contamination (contact Environmental Health and Safety; 2-6410); and
    • Comply with shipping requirements for recombinant or synthetic nucleic acid molecules (see Appendix H, Shipment, for shipping requirements and the Laboratory Safety Monograph for technical recommendations).

Go to top